Ignite Creation Date:
2024-05-06 @ 2:50 PM
Last Modification Date:
2024-10-26 @ 1:38 PM
Study NCT ID:
NCT04444466
Status:
TERMINATED
Last Update Posted:
2022-07-19
First Post:
2020-06-19
Brief Title:
A Study to Evaluate Safety Tolerability Pharmacokinetics and Pharmacodynamics of UCB8600 in Healthy Participants Atopic Participants and Chronic Spontaneous Urticaria Participants
Sponsor:
UCB Biopharma SRL
Organization:
UCB Pharma
Study Overview
Official Title:
A First-In-Human Randomized Participant-Blind Investigator-Blind Placebo-Controlled Single- and Multiple-Dose Dose-Escalating Study Evaluating the Safety Tolerability Pharmacokinetics and Pharmacodynamics of UCB8600 in Healthy Participants Atopic Participants and Chronic Spontaneous Urticaria Participants
Status:
TERMINATED
Status Verified Date:
2022-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
internal company decision not safety related
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of the study is to assess safety tolerability and pharmacokinetics PK of oral UCB8600
Detailed Description:
The Study was only open for recruitment of Healthy Study Participants Part A prior to termination and did not enroll any patient population
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| 2019-002981-12 | EUDRACT_NUMBER | None | None |